About ABUS

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ABUS is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 199.3 M 1.99301E+08 230 230 0.0% 4.94793E-05 20 K 20338
UBIO Proshares UltraPro Nasdaq Biotechnology 25.6 M 2.5617E+07 225 225 0.0% 3.27908E-05 3 K 2651
VTHR Vanguard Russell 3000 ETF 479.5 M 4.795E+08 3,004 3004 0.0% 0 30 30
VTWG Vanguard Russell 2000 Growth ETF 307.1 M 3.071E+08 1,329 1329 0.0% 0 4 4
VTWV Vanguard Russell 2000 Value ETF 258.2 M 2.582E+08 1,619 1619 0.0% 0 160 160
IBB iShares Nasdaq Biotechnology Index Fund 7.0 B 6.98667E+09 219 219 0.01% 0.0001 824 K 824138
IWC iShares Microcap ETF 800.2 M 8.00224E+08 1,388 1388 0.02% 0.0002 138 K 137763